background
compar
hc
group
risk
death
caus
higher
hc
group
adjust
hazard
ratio
ci
hcaz
group
adjust
hazard
ratio
ci
risk
ventil
similar
hc
group
adjust
hazard
ratio
ci
hcaz
group
adjust
hazard
ratio
ci
compar
hc
group
studi
found
evid
use
hydroxychloroquin
either
without
azithromycin
reduc
risk
mechan
ventil
patient
hospit
associ
increas
overal
mortal
identifi
patient
treat
hydroxychloroquin
alon
find
highlight
import
await
result
ongo
prospect
random
control
studi
widespread
adopt
drug
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
http
doi
medrxiv
preprint
rapid
pandem
exert
inordin
pressur
clinician
drug
regulatori
agenc
throughout
world
expedit
develop
approv
deploy
experiment
drug
repurpos
exist
therapeut
among
myriad
therapeut
advanc
potenti
repurpos
candid
antimalari
immunomodulatori
drug
hydroxychloroquin
captur
great
attent
follow
openlabel
nonrandom
singl
treatment
center
studi
report
efficaci
hydroxychloroquin
potenti
synergist
effect
macrolid
antibiot
azithromycin
improv
viral
clearanc
patient
result
spotlight
public
interest
led
soar
util
drug
shortag
impact
use
label
indic
stockpil
countri
subsequ
studi
identifi
similar
benefit
hydroxychloroquin
concern
rais
origin
posit
studi
nevertheless
unit
state
food
drug
administr
use
emerg
author
second
time
ever
permit
use
drug
unapprov
indic
case
hydroxychloroquin
situat
clinic
trial
unavail
infeas
multipl
prospect
random
trial
hydroxychloroquin
underway
due
cours
provid
valuabl
inform
safeti
efficaci
howev
given
increasingli
widespread
use
therapi
also
prophylaxi
great
immedi
need
obtain
insight
clinic
outcom
among
patient
current
treat
hydroxychloroquin
particularli
nonneglig
toxic
associ
use
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
certifi
peer
review
copyright
holder
preprint
version
post
april
http
doi
medrxiv
preprint
therefor
conduct
retrospect
analysi
patient
hospit
veteran
health
administr
medic
center
across
unit
state
analyz
associ
hydroxychloroquin
azithromycin
use
clinic
outcom
find
nationwid
studi
one
complet
nation
dataset
unit
state
acceler
understand
outcom
drug
await
result
ongo
prospect
trial
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
certifi
peer
review
copyright
holder
preprint
version
post
april
develop
cohort
compris
patient
laboratori
confirm
infect
inpati
set
statu
classifi
laboratori
result
extract
va
laboratori
data
text
search
laboratori
test
use
queri
va
lab
result
studi
index
date
defin
date
hospit
posit
laboratori
test
index
date
rang
march
april
patient
follow
index
hospit
discharg
death
period
prior
index
design
baselin
period
index
design
followup
period
patient
includ
studi
inform
includ
bodi
mass
index
vital
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
certifi
peer
review
copyright
holder
preprint
version
post
april
http
doi
medrxiv
preprint
sign
encount
temperatur
heart
rate
blood
pressur
discharg
disposit
statu
avail
hospit
studi
outcom
result
hospit
discharg
death
whether
ventil
requir
result
hospit
among
patient
requir
ventil
ventil
usag
code
use
hcpcscpt
code
code
result
hospit
code
discharg
disposit
statu
inpati
record
hospit
data
taken
va
inpati
hospit
data
patient
assign
one
three
cohort
base
medic
exposur
hydroxychloroquin
hc
azithromycin
az
hctreat
hcand
aztreat
hcuntreat
patient
expos
hydroxychloroquin
dispens
drug
va
bar
code
medic
administr
bcma
data
file
hospit
similarli
patient
receiv
azithromycin
hydroxychloroquin
hospit
categor
hcand
aztreat
patient
hydroxychloroquin
exposur
code
hc
unexpos
examin
associ
ventil
time
hydroxychloroquin
azithromycin
dispens
code
dynam
ventil
support
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
certifi
peer
review
copyright
holder
preprint
version
post
april
http
doi
medrxiv
preprint
baselin
date
admiss
patient
extract
demograph
comorbid
clinic
vital
sign
pharmaci
data
includ
inform
associ
increas
sever
demograph
clinic
characterist
includ
age
sex
race
bodi
mass
index
bmi
comorbid
condit
util
code
calcul
charlson
comorbid
index
relev
patient
data
vital
sign
data
includ
heart
rate
puls
oximetri
respir
temperatur
blood
pressur
bp
vital
sign
data
collect
first
set
vital
result
patient
hospit
prior
ventil
applic
laboratori
data
hospit
also
evalu
patient
consist
liver
function
test
albumin
bilirubin
creatinin
blood
urea
nitrogen
erythrocyt
hematocrit
platelet
white
blood
cell
creactiv
protein
procalcitonin
troponin
erythrocyt
sediment
rate
statist
analysi
studi
conduct
multipl
step
first
gener
summari
baselin
demograph
comorbid
clinic
characterist
cohort
treatment
group
hc
hcaz
hc
summar
differ
across
treatment
group
continu
variabl
analyz
anova
ftest
categor
variabl
chisquar
test
second
compar
frequenc
patient
requir
ventil
die
discharg
hospit
treatment
statu
use
chisquar
test
third
assess
associ
treatment
statu
studi
outcom
estim
fine
gray
compet
risk
proport
hazard
model
model
analyz
outcom
death
took
account
compet
risk
discharg
model
analyz
outcom
ventil
took
account
compet
risk
discharg
death
prior
ventil
use
fine
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
http
doi
medrxiv
preprint
gray
proport
hazard
model
estim
subdistribut
hazard
ratio
repres
instantan
event
rate
patient
experienc
event
experienc
compet
event
proport
hazard
assumpt
test
previous
describ
use
implement
within
r
packag
goftt
violat
proport
hazard
assumpt
identifi
account
nonrandom
assign
treatment
group
util
propens
score
adjust
outcom
death
death
ventil
creat
propens
score
hydroxychloroquin
use
alon
hydroxychloroquin
azithromycin
use
hospit
stay
ventil
outcom
creat
propens
score
hydroxychloroquin
use
alon
prior
ventil
hydroxychloroquin
azithromycin
use
prior
ventil
set
propens
score
estim
via
multinomi
logist
regress
treatment
group
baselin
covari
includ
propens
score
model
propens
score
enter
outcom
model
restrict
cubic
spline
statist
analys
perform
use
sa
softwar
version
sa
institut
r
softwar
version
r
project
http
rprojectorg
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
http
doi
medrxiv
preprint
identifi
patient
hospit
confirm
infect
veteran
health
administr
medic
center
across
unit
state
either
die
discharg
april
number
femal
patient
cohort
small
permit
robust
statist
analys
evalu
remain
male
patient
studi
patient
categor
three
differ
group
treat
hydroxychloroquin
hc
treat
hydroxychloroquin
azithromycin
hcaz
unexpos
hydroxychloroquin
hc
tabl
patient
receiv
standard
support
manag
signific
differ
among
three
group
baselin
demograph
characterist
select
vital
sign
laboratori
test
prescript
drug
use
comorbid
tabl
death
hc
group
death
hcaz
group
death
hc
group
tabl
mechan
ventil
occur
hc
group
hcaz
group
hc
group
tabl
analyz
associ
hc
hcaz
use
risk
overal
death
risk
ventil
primari
outcom
baselin
characterist
correspond
clinic
sever
vari
across
three
group
patient
could
influenc
nonrandom
util
hydroxychloroquin
azithromycin
comput
propens
score
hc
use
hcaz
use
base
baselin
characterist
model
analyz
outcom
death
took
account
compet
risk
discharg
model
analyz
outcom
ventil
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
http
doi
medrxiv
preprint
took
account
compet
risk
discharg
death
prior
ventil
risk
outcom
estim
use
subdistribut
hazard
regress
compar
hc
group
higher
risk
death
caus
hc
group
adjust
hr
ci
hcaz
group
adjust
hr
ci
tabl
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
http
doi
medrxiv
preprint
effect
therapi
yet
identifi
given
longer
develop
test
approv
time
novel
chemic
entiti
repurpos
drug
alreadi
approv
indic
promis
approach
rapidli
identifi
effect
therapi
hydroxychloroquin
forefront
drug
repurpos
candid
although
ongo
random
control
studi
expect
provid
inform
evid
hydroxychloroquin
come
month
outcom
observ
studi
repres
best
avail
data
nationwid
retrospect
studi
largest
integr
healthcar
system
unit
state
provid
largest
dataset
yet
report
outcom
patient
treat
hydroxychloroquin
without
azithromycin
anywher
world
specif
hydroxychloroquin
use
without
coadministr
azithromycin
improv
mortal
reduc
need
mechan
ventil
hospit
patient
contrari
hydroxychloroquin
use
alon
associ
increas
risk
mortal
compar
standard
care
alon
baselin
demograph
comorbid
characterist
compar
across
three
treatment
group
howev
hydroxychloroquin
without
azithromycin
like
prescrib
patient
sever
diseas
assess
baselin
ventilatori
statu
metabol
hematolog
paramet
thu
expect
increas
mortal
observ
patient
treat
hydroxychloroquin
without
azithromycin
nevertheless
increas
risk
overal
mortal
hydroxychloroquineonli
group
persist
adjust
propens
treat
drug
increas
risk
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
http
doi
medrxiv
preprint
ventil
hydroxychloroquineonli
group
suggest
mortal
group
might
attribut
drug
effect
dysfunct
nonrespiratori
vital
organ
system
inde
hydroxychloroquin
use
patient
associ
cardiac
toxic
hydroxychloroquin
report
inhibit
replic
vitro
maxim
effect
concentr
rang
howev
approv
dose
regimen
hydroxychloroquin
patient
rheumatoid
arthriti
lupu
gener
substanti
lower
peak
serum
drug
concentr
administ
higher
dose
hydroxychloroquin
achiev
presum
antivir
concentr
might
increas
risk
advers
event
interestingli
random
control
trial
highdos
chloroquin
parent
compound
hydroxychloroquin
also
report
vitro
antivir
activ
similar
peak
serum
concentr
human
halt
prematur
due
cardiac
toxic
higher
fatal
rate
highdos
chloroquinetr
patient
studi
certain
limit
includ
inher
retrospect
analys
nonrandom
treatment
howev
adjust
larg
number
covid
abnorm
despit
propens
score
adjust
larg
number
relev
confound
rule
possibl
select
bia
residu
confound
studi
cohort
compris
men
whose
median
age
year
therefor
result
may
necessarili
reflect
outcom
women
younger
hospit
popul
extrapol
pediatr
patient
find
may
also
influenc
demograph
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
http
doi
medrxiv
preprint
composit
patient
cohort
major
black
disproportion
higher
rate
hospit
among
black
popul
also
report
unit
state
whole
studi
also
certain
strength
studi
data
comprehens
electron
medic
record
rather
administr
health
insur
claim
databas
use
rigor
identifi
covari
outcom
studi
patient
integr
nation
healthcar
system
therefor
data
less
suscept
bias
singlecent
region
studi
data
ongo
random
control
studi
prove
inform
emerg
find
retrospect
studi
suggest
caution
use
hydroxychloroquin
hospit
patient
particularli
combin
azithromycin
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
http
doi
medrxiv
preprint
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
http
doi
medrxiv
preprint
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
certifi
peer
review
copyright
holder
preprint
version
post
april
http
doi
medrxiv
preprint
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
certifi
peer
review
copyright
holder
preprint
version
post
april
http
doi
medrxiv
preprint
associ
treatment
outcom
use
compet
risk
hazard
regress
adjust
clinic
characterist
via
propens
score
discharg
death
taken
account
compet
risk
subdistribut
hazard
ratio
present
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
certifi
peer
review
copyright
holder
preprint
version
post
april
http
doi
medrxiv
preprint
